Valeant Pharma expects 3Q revenue to top forecasts

Published



Shares of Valeant Pharmaceuticals International Inc. climbed Wednesday after the Canadian drugmaker said it expects market share gains in most of its businesses and that its third-quarter revenue will top forecasts.

The drugmaker also said it expects 10 percent growth from the established business of its contact lens maker Bausch + Lomb, a target of criticism in Valeant’s on-going takeover battle with Botox-maker Allergan Inc.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.